	submission_name	submission_date	second_spot_check	spot_check	template_name	tissue_type	tissue_type_term_id	response_component	response_behavior_type	response_behavior	subgroup	time_point	time_point_units	baseline_time	target_pathogen	target_pathogen_taxonid	vaccine_year	exposure_material_text	exposure_material	additional_exposure_material	Group1	addntl_time_point_units	Group0	comparison	number_subjects	cohort	adjuvant	route	scheduling	publication_reference	publication_year	signature_source	signature_source_url	comments	short_comment	process_note	publication_reference_url	age_group	age_min	age_max	age_units	extra_comments
subject						cell_subset		cell_subset							pathogen				vaccine																							
evidence									label	label	label	label	label	label			label	label		label	label	label	label	label	label	label	label	label	label	label	label	label	label	label	label	label	url	label	label	label	label	label
role						tissue		cell_biomarker	background	measured	background	observed	observed	background	pathogen		background	background	vaccine	background	observed	observed	observed	background	observed	observed	background	background	background	background	background	background	background	background	background	background	reference	observed	observed	observed	observed	observed
mime_type																																										
numeric_units																																										
display_text						tissue type	Cell Ontology ID	response component (cell subset)	response behavior type	response behavior	subgroup	time point	time point units	baseline time	target pathogen	NCBI TaxonID (non-influenza)	vaccine year	exposure material (name)	exposure material (VO)	exposure material - additional	Group1	addntl time point units	Group0	comparison	number of subjects	cohort	adjuvant	route	scheduling	publication reference (PMID)	publication year	signature source figure, table or text section	signature source url	comments and additional details	short comment for mSigDB standard name	internal use only	publication url	cohort	age min.	age max.	age units	will not appear in Dashboard
			daniel	Daniel: added source		blood	UBERON_0000178	antibody secreting cell	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Neisseria meningitidis			Menactra; Menomune	VO_0000071; VO_0000072					Menactra vs Menomune		adults (18-45)				24336226	2014	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F1/				https://www.ncbi.nlm.nih.gov/pubmed/?term=24336226	adults	18	45	years	
				Daniel:curated		blood	UBERON_0000178	antibody secreting cell	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Neisseria meningitidis			Menactra	VO_0000071					d7 vs d0		adults (18-45)				24336226	2014	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F1/				https://www.ncbi.nlm.nih.gov/pubmed/?term=24336226	adults	18	45	years	
				Daniel:curated		blood	UBERON_0000178	antibody secreting cell	cell type frequency	up for	none	30	Days	time of vaccination (first dose)	Neisseria meningitidis			Menactra	VO_0000071					d30 vs d0		adults (18-45)				24336226	2014	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F1/				https://www.ncbi.nlm.nih.gov/pubmed/?term=24336226	adults	18	45	years	
				Daniel:curated		blood	UBERON_0000178	antibody secreting cell	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Neisseria meningitidis			Menomune	VO_0000072					d7 vs d0		adults (18-45)				24336226	2014	Fig 1F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F1/				https://www.ncbi.nlm.nih.gov/pubmed/?term=24336226	adults	18	45	years	
			daniel	Daniel: added source		blood	UBERON_0000178	antibody secreting cell	cell type frequency	positively correlated with 	none	7	Days	time of vaccination (first dose)	Neisseria meningitidis			Menactra	VO_0000071					d7 serum anti-DT IgG		adults (18-45)				24336226	2014	Fig 1G	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F1/				https://www.ncbi.nlm.nih.gov/pubmed/?term=24336226	adults	18	45	years	
				Daniel: re-curated		peripheral blood mononuclear cell	CL:2000001	central memory CD4-positive, alpha-beta T cell; effector memory CD8-positive, alpha-beta T cell	cell type frequency	negatively predictive of		0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2008	Fluzone	VO_0000047					d28 HAI		adults				23591775	2013	Fig 5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658270/figure/f5/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23591775	adults				
			Amani: changed source, added subgroup	Daniel: re-curated		peripheral blood mononuclear cell	CL:2000001	central memory CD4-positive, alpha-beta T cell; effector memory CD8-positive, alpha-beta T cell; CD8-positive, CD28-negative, alpha-beta regulatory T cell; natural killer cell	cell type frequency	negatively predictive of	good responders	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2008	Fluzone	VO_0000047					d28 HAI		adults				23591775	2013	Suppl Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658270/#S1				https://www.ncbi.nlm.nih.gov/pubmed/?term=23591775	adults				
			Amani: changed source, added subgroup	Daniel: re-curated		peripheral blood mononuclear cell	CL:2000001	naive thymus-derived CD8-positive, alpha-beta T cell	cell type frequency	positively predictive of	good responders	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2008	Fluzone	VO_0000047					d28 HAI		adults				23591775	2013	Suppl Fig 3	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658270/#S1				https://www.ncbi.nlm.nih.gov/pubmed/?term=23591775	adults				
				Daniel: re-curated		peripheral blood mononuclear cell	CL:2000001	central memory CD4-positive, alpha-beta T cell; effector memory CD8-positive, alpha-beta T cell	cell type frequency	negatively predictive of		28	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2008	Fluzone	VO_0000047					d28 HAI		adults				23591775	2013	Fig 5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658270/figure/f5/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23591775	adults				
				Daniel: re-curated		peripheral blood mononuclear cell	CL:2000001	central memory CD4-positive, alpha-beta T cell; effector memory CD8-positive, alpha-beta T cell; CD8-positive, CD28-negative, alpha-beta regulatory T cell; natural killer cell	cell type frequency	negatively predictive of	none	28	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2008	Fluzone	VO_0000047					d28 HAI		adults				23591775	2013	Fig 7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658270/figure/f7/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23591775	adults				
				Daniel: re-curated		peripheral blood mononuclear cell	CL:2000001	naive thymus-derived CD8-positive, alpha-beta T cell	cell type frequency	positively predictive of	none	28	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2008	Fluzone	VO_0000047					d28 HAI		adults				23591775	2013	Fig 7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658270/figure/f7/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23591775	adults				
			daniel, removed 'b cell' agent'	Daniel: added source		blood	UBERON_0000178	plasmablast	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Streptococcus pneumoniae			Pneumovax 23	VO_0000088					7d vs 0d		adults (18-64)				23601689	2013	Fig 6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681204/figure/F6/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23601689	adults, seniors	18	64	years	
			daniel, removed 'b cell' agent'	Daniel: added source		blood	UBERON_0000178	plasmablast	cell type frequency	up for	none	10	Days	time of vaccination (first dose)	Streptococcus pneumoniae			Pneumovax 23	VO_0000088					10d vs 0d		adults (18-64)				23601689	2013	Fig 6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681204/figure/F6/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23601689	adults, seniors	18	64	years	
			daniel, removed 'b cell' agent'	Daniel: added source, edited comparison & response behavior		blood	UBERON_0000178	plasmablast	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009	Fluzone	VO_0000047					7d vs 0d		adults (18-64)				23601689	2013	Fig 6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681204/figure/F6/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23601689	adults, seniors	18	64	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL_2000001	CD56-bright natural killer (NK) cells	cell type frequency	positively correlated with 	none	3	Days	time of vaccination (first dose)	Ebola virus			rVSV-EBOV	VO_0004660					antibody response at 28d and onward		adults (18-55)				28854372	2017	Fig 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/figure/fig4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/	adults	18	55	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL_2000001	switched IgG+ memory B cells (CD3-, CD19+, HLADR+, CD27+, IgG+); IgG+ memory B cells (CD3-, CD19+, HLADR+, CD27+, CD10-, CD20+, IgG+)	cell type frequency	negatively correlated with 	none	3	Days	time of vaccination (first dose)	Ebola virus			rVSV-EBOV	VO_0004660					antibody response at 28d and onward		adults (18-55)				28854372	2017	Fig 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/figure/fig4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/	adults	18	55	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL_2000001	CD86+ myeloid dendritic cells (mDCs); CCR7+ myeloid dendritic cells (mDCs); CD40/CD86+ monocytes; CD38+ CD56-dim natural killer (NK) cells	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Ebola virus			rVSV-EBOV	VO_0004660					1d vs 0d		adults (18-55)				28854372	2017	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/figure/fig2/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/	adults	18	55	years	
			daniel, added CD40/CD86+ plasma dendritic cells (pDCs)  to this entryâ€”it used to be on its own line with comparison d3-d1, but i think it's a d3-d0 comparison and the authors got lazy with drawing their bars	Amani: added source		peripheral blood mononuclear cell	CL_2000001	CD40/CD86+ plasma dendritic cells (pDCs); CD86+ myeloid dendritic cells (mDCs); CD86+ CD16+ inflammatory monocytes; CD40/CD86+ monocytes; CD16+ inflammatory monocytes; CD38+ CD56dim natural killer (NK) cells; NKG2D+ CD56dim natural killer (NK) cells; CD56bright natural killer (NK) cells	cell type frequency	up for	none	3	Days	time of vaccination (first dose)	Ebola virus			rVSV-EBOV	VO_0004660					3d vs 0d		adults (18-55)				28854372	2017	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/figure/fig2/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/	adults	18	55	years	
			daniel, split two vaccines into two rows	Amani: added source		peripheral blood mononuclear cell	CL:2000001	interferon-gamma-positive T cells	cell type frequency	up for	none	28	Days	time of vaccination (second dose)	Influenza A virus; Influenza B virus		2012	Imuvac	VO_0003144					28d (postboost) vs 0d (pre-imm)		children (14-26mo)				26755593	2016	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/figure/fig02/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/	children	14	26	months	
			daniel, split from previous row	Amani: added source		peripheral blood mononuclear cell	CL:2000001	interferon-gamma-positive T cells	cell type frequency	up for	none	28	Days	time of vaccination (second dose)	Influenza A virus; Influenza B virus		2012	Fluad	VO_0004281					28d (postboost) vs 0d (pre-imm)		children (14-26mo)				26755593	2016	Fig 2B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/figure/fig02/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/	children	14	26	months	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	intereferon-gamma-positive, tumor-necrosis-factor-alfa-positive, interleukin-2-positive, effector memory CD4-positive, alpha-beta T cell; intereferon-gamma-negative, tumor-necrosis-factor-alfa-positive, interleukin-2-positive, effector memory CD4-positive, alpha-beta T cell	cell type frequency	up for	none	28	Days	time of vaccination (second dose)	Influenza A virus; Influenza B virus		2012	Fluad	VO_0004281					28d (postboost) vs 0d (pre-imm)		children (14-27mo)				26755593	2016	Fig 2A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/figure/fig02/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/	children	14	27	months	
				Daniel:added source, edited direction, moved agents to new line; removed 'granulocyte' and 'lymphocyte' from response agents (no source)		peripheral blood mononuclear cell	CL:2000001	B cell;  CD4+ alpha-beta T cell; CD16+ CD56dim natural killer cell; CD8+ alpha-beta T cell; granulocyte; lymphocyte	cell type frequency	down for	none	1	Days	time of vaccination (first dose)	Human immunodeficiency virus 1 			MRKAd5/HIV	VO_0003133					1d vs 0d		adults (20-50)				23151505	2012	Fig. 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/figure/fig01/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/	adults	20	50	years	
				Daniel: from previous line, edited direction		peripheral blood mononuclear cell	CL:2000001	CD14+ CD16- classical monocyte	cell type frequency	up for	none	1	Days	time of vaccination (first dose)	Human immunodeficiency virus 1 			MRKAd5/HIV	VO_0003133					1d vs 0d		adults (20-50)				23151505	2012	Fig. 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/figure/fig01/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/	adults	20	50	years	
				Daniel:added source, edited direction, moved agents to new line, removed granulocytes (no source)		peripheral blood mononuclear cell	CL:2000001	CD14+ CD16- classical monocyte; CD16+ CD56-dim natural killer cell	cell type frequency	up for	none	3	Days	time of vaccination (first dose)	Human immunodeficiency virus 1 			MRKAd5/HIV	VO_0003133					3d vs 0d		adults (20-50)				23151505	2012	Fig. 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/figure/fig01/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/	adults	20	50	years	
				Daniel: from previous line, edited direction		peripheral blood mononuclear cell	CL:2000001	B cell	cell type frequency	down for	none	3	Days	time of vaccination (first dose)	Human immunodeficiency virus 1 			MRKAd5/HIV	VO_0003133					3d vs 0d		adults (20-50)				23151505	2012	Fig. 1E	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/figure/fig01/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/	adults	20	50	years	
				Daniel: added source		peripheral blood mononuclear cell	CL:2000001	CD4-positive, CD25-positive, alpha-beta regulatory T cell	cell type frequency	up for	low responders	7	Days	time of vaccination (first dose)	Mycobacterium tuberculosis variant bovis BCG			Modified Vaccinia Ankara (MVA) virus vaccine vector	VO_0003120					7d vs 0d		adult (18-55)				23844129	2013	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700883/figure/pone-0067922-g002/				https://www.ncbi.nlm.nih.gov/pubmed/?term=23844129	adults	18	55	years	
				Daniel: added source, adjusted time point		peripheral blood mononuclear cell	CL:2000001	plasma cell	cell type frequency	positively correlated with 	none	7	Days	time of vaccination (first dose)	Neisseria meningitidis			Menveo; ACWYVax	VO_0001246; VO_0003138					MenC SBA at day 28		adults (30-70)				28137280	2017	Table 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282650/table/Tab2/				https://www.ncbi.nlm.nih.gov/pubmed/?term=28137280	adults, seniors	30	70	years	
			daniel: edited response component	Amani: added source		peripheral blood mononuclear cell	CL:2000001	IFN-gamma+ antigen specific T cell	cell type frequency	up for	none	8	Days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					8d vs 0d		seniors (50-75)				27764254	2016	Fig 1a, text	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/figure/ppat.1005892.g001/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/	adults, seniors	50	75	years	
			daniel: edited response component	Amani: added source		peripheral blood mononuclear cell	CL:2000001	IFN-gamma+ antigen specific T cell	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					14d vs 0d		seniors (50-75)				27764254	2016	Fig 1a, text	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/figure/ppat.1005892.g001/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/	adults, seniors	50	75	years	
			daniel: edited response component	Amani: added source		peripheral blood mononuclear cell	CL:2000001	IFN-gamma+ antigen specific T cell	cell type frequency	up for	none	28	Days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					28d vs 0d		seniors (50-75)				27764254	2016	Fig 1a, text	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/figure/ppat.1005892.g001/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/	adults, seniors	50	75	years	
			daniel: edited response component	Amani: added source		peripheral blood mononuclear cell	CL:2000001	IFN-gamma+ antigen specific T cell	cell type frequency	down for	none	28	Days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					28d vs 8d		seniors (50-75)				27764254	2016	Fig 1a, text	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/figure/ppat.1005892.g001/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/	adults, seniors	50	75	years	
			daniel: edited source	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD38+HLADR+ VZV tetramer+ cells (% of VZV tetramer CD4 T cells)	cell type frequency	up for	none	8	Days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					8d vs 0d		seniors (50-75)				27764254	2016	Fig 6b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/figure/ppat.1005892.g006/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/	adults, seniors	50	75	years	
			daniel: edited source	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD38+ HLADR+ VZV tetramer+ cells (% of VZV tetramer CD4 T cells)	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					14d vs 0d		seniors (50-75)				27764254	2016	Fig 6b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/figure/ppat.1005892.g006/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/	adults, seniors	50	75	years	
				Daniel: added source; also removed a signature that was identical to this one but for d57-d0 (couldn't find source)		peripheral blood mononuclear cell	CL:2000001	interferon-gamma+ CD4 T cells	cell type frequency	up for	none	29	Days	time of vaccination (first dose)	Mycobacterium tuberculosis variant bovis BCG			VPM1002	VO_0003131					29d vs 0d		adults (18-55)				23290835	2013	Fig 3A	https://www.sciencedirect.com/science/article/pii/S0264410X12018403?via%3Dihub#fig0015				https://www.ncbi.nlm.nih.gov/pubmed/?term=23290835	adults	18	55	years	
				Daniel: added source		peripheral blood mononuclear cell	CL:2000001	triple-positive (interferon-gamma, tumor necrosis factor-alpha, interleukin-2) CD4 T cells	cell type frequency	up for	none	29	Days	time of vaccination (first dose)	Mycobacterium tuberculosis variant bovis BCG			BCG vaccine; VPM1002	VO_0000771; VO_0003131					VPM1002-3 vs BCG vaccine		adults (18-55)				23290835	2013	Fig 3B	https://www.sciencedirect.com/science/article/pii/S0264410X12018403?via%3Dihub#fig0015				https://www.ncbi.nlm.nih.gov/pubmed/?term=23290835	adults	18	55	years	
				Daniel: added source		blood	UBERON_0000178	CD8+ interleukin-17+ (IL-17+) cells	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Mycobacterium tuberculosis variant bovis BCG			BCG vaccine; VPM1002	VO_0000771; VO_0003131					14d vs 0d		infants				27974398	2017	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299117/figure/F4/				https://www.ncbi.nlm.nih.gov/pubmed/?term=27974398	infants				
				Daniel: added source		blood	UBERON_0000178	CD8+ interleukin-17+ (IL-17+) cells	cell type frequency	up for	none	6	Months	time of vaccination (first dose)	Mycobacterium tuberculosis variant bovis BCG			BCG vaccine; VPM1002	VO_0000771; VO_0003131					6m vs 0m		infants				27974398	2017	Fig 4B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299117/figure/F4/				https://www.ncbi.nlm.nih.gov/pubmed/?term=27974398	infants				
				Daniel: added source, removed red blood cells as agent bc authors specify only the other cell types as significant 		peripheral blood mononuclear cell	CL:2000001	white blood cell; neutrophil; lymphocyte; eosinophil	cell type frequency	down for	none	7	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-VAX	VO_0000121					7d vs 0d		adults (18-40)				17651872	2007	Text: Study Summaries and Clinical Observations					https://www.ncbi.nlm.nih.gov/pubmed/?term=17651872	adults	18	40	years	
				Daniel: re-curated		blood	UBERON_0000178	switched IgG+ memory B cells (CD3-, CD19+, HLADR+, CD27+, IgG+); IgG+ memory B cells (CD3-, CD19+, HLADR+, CD27+, CD10-, CD20+, IgG+)	cell type frequency	positively predictive of	none	0	Days	time of vaccination (first dose)	Hepatitis B virus			Twinrix	VO_0000113					anti-HBsAg ab titre		seniors (65-83)				26742691	2016	Fig 5b; Table 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729923/table/t1/	EM131 elderly cohort (65-83)			https://www.ncbi.nlm.nih.gov/pubmed/?term=26742691	seniors	65	83	years	
				Daniel: re-curated		blood	UBERON_0000178	TEM2+ CD4+ T Cell; CD40+ pDC	cell type frequency	positively correlated with 	none	0	Days	time of vaccination (first dose)	Hepatitis B virus			Twinrix	VO_0000113					anti-HBsAg ab titre		seniors (65-83)				26742691	2016	Fig 5a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729923/figure/f5	EM131 elderly cohort (65-83)			https://www.ncbi.nlm.nih.gov/pubmed/?term=26742691	seniors	65	83	years	
				Daniel: added source		peripheral blood mononuclear cell	CL:2000001	memory B cell	cell type frequency	up for	none	28	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluarix	VO_0000045					28d vs 0d		adults(50-74)				27317456	2016	Text: Subjects Demographics and Memory B cell ELISPOT response					https://www.ncbi.nlm.nih.gov/pubmed/?term=27317456	adults, seniors	50	74	years	
			daniel: edited source	Amani: added source		peripheral blood mononuclear cell	CL:2000001	IgG+ Antibody secreting cells	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009, pan	Fluvirin; Pandemrix	VO_0000046; VO_0000410					7d vs 0d		adults				24725414	2014	Fig 3a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/	adults				
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD40+ monocytes; CD38+ of CD8+ T cells; CD86+ monocytes; CD86+ of naive B cells; CD69+ of CD8+ T cells; CD25+ of CD8+ Tcells; CD38+ of IgD+CD27+ memory B cells; IL2+ of CD4+ T cells; HLA-DR+ of CD4+ T cells; CD103+ of CD4+ T cells; CD14+ of viable CD45+ cells (Total monocytes); CD80+ of IgD-CD27+ memory B cells; CD103+ of CD8+ T cells; IFNa+ of pDCs; HLA-DR+ of CD8+ T cells; IL4+ of CD4+ T cells	cell type frequency	up for	none	1	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009, pan	Fluvirin; Pandemrix	VO_0000046; VO_0000410					1d vs 0d		adults				24725414	2014	Fig 3d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/	adults				
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD21+ plasmablast; IgA+ of IgD-CD27+ memory B cells	cell type frequency	down for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009, pan	Fluvirin; Pandemrix	VO_0000046; VO_0000410					7d vs 0d		adults				24725414	2014	Fig 3d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/	adults				
			daniel: edited response components... not sure where the original list: "CD86+ myeloid dendritic cells (mDCs); CCR7+ myeloid dendritic cells (mDCs); CD40/CD86+ monocytes; CD38+ CD56dim natural killer (NK) cells" came from	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD27hi CD38hi of CD20- B cells (plasmablasts); CD38+ of IgD-CD27+ memory B cells; CD86+ of CD20+ B cells; CD38+ of CD4+ T cells; CD86+ of Naive B Cells; IL4+ of CD4+ T cells; CD39+ of CD8+ T cells; CD86+ of IgD-CD27- memory B cells	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009, pan	Fluvirin; Pandemrix	VO_0000046; VO_0000410					7d vs 0d		adults				24725414	2014	Fig 3d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/	adults				
			daniel: edited comparison, titers are measured at baseline, removed subgroup (high vs low comparison)	Amani: added source		peripheral blood mononuclear cell	CL:2000001	plasmablast	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009, pan	Fluvirin; Pandemrix	VO_0000046; VO_0000410					low baseline titer group vs high baseline titer group		adults				24725414	2014	Fig 4c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/	adults				
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	IL22+ of CD161- CD4+ T cells; IL2+ of CD4+ T cells; CD38+ of transitional B cells; CD38+ of CD20+IgD-CD27+ B cells; CD38+ of IgD+CD27+ memory B cells; CD38+ of Naive B cells	cell type frequency	positively predictive of	none	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009, pan	Fluvirin; Pandemrix	VO_0000046; VO_0000410					d28 HAI		adults				24725414	2014	Fig 6c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F6/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/	adults				
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	CD27+CCR7- of memory CD4+ T cells;	cell type frequency	negatively predictive of	none	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2009, pan	Fluvirin; Pandemrix	VO_0000046; VO_0000410					d28 HAI		adults				24725414	2014	Fig 6c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F6/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/	adults				
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	influenza-specific IgG secreting plasmablasts	cell type frequency	positively correlated with 	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2007, 2008, 2009	Fluarix; Fluvirin	VO_0000045; VO_0000046					HAI response at 28 days		young adults (18-50yrs)				21743478	2011	Fig 1e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/	adults	18	50	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	influenza-specific IgM secreting plasmablasts	cell type frequency	positively correlated with 	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2007, 2008, 2009	Fluarix; Fluvirin	VO_0000045; VO_0000046					HAI response at 28 days		young adults (18-50yrs)				21743478	2011	Supp Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/#SD1				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/	adults	18	50	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	influenza-specific IgA secreting plasmablasts	cell type frequency	positively correlated with 	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2007, 2008, 2009	Fluarix; Fluvirin	VO_0000045; VO_0000046					HAI response at 28 days		young adults (18-50yrs)				21743478	2011	Supp Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/#SD1				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/	adults	18	50	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	influenza-specific IgG secreting plasmablasts	cell type frequency	positively correlated with 	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2007, 2008, 2009	Fluarix; Fluvirin	VO_0000045; VO_0000046					total plasmablast		young adults (18-50yrs)				21743478	2011	Fig 1d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/	adults	18	50	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	influenza-specific IgG secreting plasmablasts	cell type frequency	positively correlated with 	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2008	FluMist	VO_0000044 					total plasmablast		young adults (18-50yrs)				21743478	2011	Fig 1d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/	adults	18	50	years	
			daniel	Amani		blood	UBERON_0000178	naive B cells (CD19-positive, IgD-negative, CD27-negative) (CL_0000788); memory B cells (CD19+, IgD-, CD27+) (CL_0001053); transitional B cells (CD19+, CD24+, CD38+) (CL_0000818)	cell type frequency	up for	none	27 to 33	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluzone	VO_0000047					(27 to 33d) vs 0d	29	children (0.5-14yrs)				24495909	2014	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/figure/JIU079F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/	infants, children	0.5	14	years	
			daniel	Amani		blood	UBERON_0000178	plasmablasts (CD19+, CD27+, CD38+)	cell type frequency	up for	none	6 to 8	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluzone	VO_0000047					(6 to 8)d vs 0d	29	children (0.5-14yrs)				24495909	2014	Fig 1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/figure/JIU079F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/	infants, children	0.5	14	years	
			daniel	Amani		blood	UBERON_0000178	plasmablast; plasma cell	cell type frequency	positive	none	6 to 8	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluzone	VO_0000047					(27 to 33d) vs 0d	29	children (0.5-14yrs)				24495909	2014	Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/figure/JIU079F2/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/	infants, children	0.5	14	years	
			daniel	Amani		blood	UBERON_0000178	plasmablast	cell type frequency	positively correlated with 	none	6 to 8	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluzone	VO_0000047					VN titer to B strain at 27 to 33 days	29	children (0.5-14yrs)				24495909	2014	Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/figure/JIU079F2/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/	infants, children	0.5	14	years	
			daniel	Amani		blood	UBERON_0000178	plasma cell	cell type frequency	positively correlated with 	none	6 to 8	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluzone	VO_0000047					VN titer to H1N1, H3N2, B strains at 27 to 33 days	29	children (0.5-14yrs)				24495909	2014	Fig 2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/figure/JIU079F2/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/	infants, children	0.5	14	years	
			daniel: edited source	Amani		blood	UBERON_0000178	plasmablast	cell type frequency	positively correlated with 	none	6 to 8	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	FluMist	VO_0000044 					H3N2 VN titer at 27 to 33 days	29	children (0.5-14yrs)				24495909	2014	Text: Antibody-Secreting Cells Correlate With Antibody Titers on TIV Recipients					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/	infants, children	0.5	14	years	
			daniel: split row	Amani: added source		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors			years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD56dim CD16++ natural killer cells	cell type frequency	up for	none	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/	5A is comparisions within group against baseline			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors			years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD56++ natural killer cells; CD56++ CD16+ Natural Killer cells	cell type frequency	up for	none	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					adults vs seniors		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors			years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors			years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	3	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors			years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors			years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors			years	
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1d vs 0d		seniors (>65yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	3	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					3d vs 0d		seniors (>65yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					14d vs 0d		seniors (>65yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
			daniel: removed comment from comparison	Amani: added source		peripheral blood mononuclear cell	CL:2000001	natural killer cell	cell type frequency	down	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1d vs 0d		adults (<65yrs)				26682988	2015	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD56++ NK cells; CD56++ CD16+ NK cells	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					7d vs 0d		adults (<65yrs)				26682988	2015	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel	Amani: merged rows, added source		peripheral blood mononuclear cell	CL:2000001	CD56dim CD16++ NK cells; Natural Killer cells	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1 vs 0d		seniors (>65yrs)				26682988	2015	Fig 5A&C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD56++ NK cells; CD56++ CD16+ NK cells	cell type frequency	down for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1d vs 0d		seniors (>65yrs)				26682988	2015	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
			daniel: separated age groups	Amani: added source		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1d vs 0d		adults (<65yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel: separated age groups	Amani: added source		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1d vs 0d		seniors (>65yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
			daniel: separated age groups	Amani: added source		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	down for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					7d vs 0d		adults (<65yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel: separated age groups, edited cohort	Amani: added source		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	down for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					7d vs 0d		seniors (>65yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	up for	none	0	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors				
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	up for	none	1	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors				
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	up for	none	3	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors				
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors				
				daniel: curated		peripheral blood mononuclear cell	CL:2000001	monocytes	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					seniors vs adults		seniors (>65yrs), adults (<65 yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults, seniors				
			daniel: unmerged rows, different sources	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD14+ CD16- monocytes	cell type frequency	down for	none	3	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					3d vs 0d		adults (<65yrs)				26682988	2015	Fig S6C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel: unmerged rows, different sources	Amani: merged rows, added source		peripheral blood mononuclear cell	CL:2000001	CD14+ CD16+ monocytes	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1d vs 0d		adults (<65yrs)				26682988	2015	Fig S6C	 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel: unmerged rows, different sources	Amani: merged rows, added source		peripheral blood mononuclear cell	CL:2000001	CD56++ CD16+ natural killer (NK) cells	cell type frequency	up for	none	1	Day	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					1d vs 0d		adults (<65yrs)				26682988	2015	Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel	Amani: edited response, added source		peripheral blood mononuclear cell	CL:2000001	CD14dim CD16++ monocytes	cell type frequency	up for	none	3	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					3d vs 0d		adults (<65yrs)				26682988	2015	Fig S6C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	adults		65	years	
			daniel: unmerged rows, different sources	Amani: merged rows, added source		peripheral blood mononuclear cell	CL:2000001	CD14+ CD16- monocytes	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					14d vs 0d		seniors (>65yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD14+ CD16+ monocytes	cell type frequency	down for	none	14	Days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Inactivated influenza vaccine	VO_0001176					14d vs 0d		seniors (>65yrs)				26682988	2015	Fig S6B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/#S15title				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859820/	seniors	65		years	
			daniel: M cluster N257 will need downstream cell type checking, removed subgroup (included in comparison); bhav: M cluster N257 is not a cell type (it's a plasma metabolite cluster), so it has been removed from the signature	Amani: added source		peripheral blood mononuclear cell	CL:2000001	activated CD4+ T cells	cell type frequency	down for	none	7	Days	time of vaccination (first dose)	Human alphaherpesvirus 3			Zostavax	VO_0000124					high vs low inositol phosphate metabolism		adults (25-40/60-79)				28502771	2017	Fig 7F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711477/figure/F7/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711477/	adults, seniors	25	79	years	
			daniel: removed subgroup ( included in comparison)	Amani: added source		peripheral blood mononuclear cell	CL:2000001	neutrophil	cell type frequency	down for	none	3	Days	time of vaccination (first dose)	Human alphaherpesvirus 3			Zostavax	VO_0000124					high vs low inositol phosphate metabolism		adults (25-40/60-79)				28502771	2017	Fig 7F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711477/figure/F7/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711477/	adults, seniors	25	79	years	
			daniel	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	VZV antigen-reactive CD4 T cells	cell type frequency	up for	none	8	Days	time of vaccination (first dose)	Human alphaherpesvirus 3			Zostavax	VO_0000124					8d vs 0d		seniors (52-75)				27030598	2016	text right before Fig 3, Fig 3a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/figure/F3/	Influence of vaccination on the CD4 T cell receptor repertoire of VZV-reactive cells			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/	adults, seniors	52	75	years	
			daniel	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	VZV antigen-reactive CD4 T cells	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Human alphaherpesvirus 3			Zostavax	VO_0000124					14d vs 0d		seniors (52-75)				27030598	2016	text right before Fig 3, Fig 3a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/figure/F3/	Influence of vaccination on the CD4 T cell receptor repertoire of VZV-reactive cells			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/	adults, seniors	52	75	years	
			daniel	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	VZV antigen-reactive CD4 T cells	cell type frequency	up for	none	28	Days	time of vaccination (first dose)	Human alphaherpesvirus 3			Zostavax	VO_0000124					28d vs 0d		seniors (52-75)				27030598	2016	text right before Fig 3, Fig 3a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/figure/F3/	Influence of vaccination on the CD4 T cell receptor repertoire of VZV-reactive cells			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/	adults, seniors	52	75	years	
			daniel	Amani: added source, edited comparison & subgroup		blood	UBERON_0000178	white blood cell	cell type frequency	up for	males in group 2 (4mo: HBV & OPV. 9mo: MV+DTP (i.m). 11mo: outstanding vaccines)	28	Days	time of vaccination (first dose)	Measles virus strain Edmonston-Zagreb; Corynebacterium diphtheriae; Clostridium tetani; Human poliovirus 1; Human poliovirus 2; Human poliovirus 3			Measles virus vaccine; Diphtheria-Tetanus-Pertussis vaccine	VO_0000654; VO_0000738					group 2 (4mo: HBV and OPV. 9mo: MV+DTP (i.m). 11mo: outstanding vaccines) vs groups 1 (4mo: 3rd dose of DTP, HBV, OPV. 9mo: 1 i.m dose of MV Edmonstron Zagreb strain. 11mo: outstanding vaccines) and 3 (4mo: HBV and OPV. 9mo: DTP. 11mo: outstanding vaccines) 		infants (4mo)				27436422	2016	Table 1	https://academic.oup.com/view-large/78928196				https://academic.oup.com/cid/article/63/9/1213/2576500	infants	4	4	months	
			daniel	Amani: added source, edited comparison & subgroup		blood	UBERON_0000178	lymphocyte	cell type frequency	down for	males in group 2 (4mo: HBV & OPV. 9mo: MV+DTP (i.m). 11mo: outstanding vaccines)	28	Days	time of vaccination (first dose)	Measles virus strain Edmonston-Zagreb; Corynebacterium diphtheriae; Clostridium tetani; Human poliovirus 1; Human poliovirus 2; Human poliovirus 3			Measles virus vaccine; Diphtheria-Tetanus-Pertussis vaccine	VO_0000654; VO_0000738					group 2 (4mo: HBV and OPV. 9mo: MV+DTP (i.m). 11mo: outstanding vaccines) vs groups 1 (4mo: 3rd dose of DTP, HBV, OPV. 9mo: 1 i.m dose of MV Edmonstron Zagreb strain. 11mo: outstanding vaccines) and 3 (4mo: HBV and OPV. 9mo: DTP. 11mo: outstanding vaccines) 		infants (4mo)				27436422	2016	Table 1	https://academic.oup.com/view-large/78928196				https://academic.oup.com/cid/article/63/9/1213/2576500	infants	4	4	months	
			daniel: edited sources	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	plasmacytoid dendritic cell; NK Cells (CD14-/CD19-/CD3-/NK/CD107A+/K562); NK Cells (CD14-/CD19-/CD3-/NK/IFNg+/K562); NK Cells (CD14-/CD19-/CD3-/NK/TNFa+/K562)	cell type frequency	up for	none	7	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					7d vs 0d		adults (25-42)				28687661	2017	Fig 4g-i	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split into two rows based on figure source	Amani: added source		peripheral blood mononuclear cell	CL:2000001	NK cells (CD14-/CD20-/CD3-/NK); NK cells (CD14-/CD20-/CD3-/NK/NKG2A+); NK cells (CD14-/CD20-/CD3-/NK/NKP46+)	cell type frequency	down for	none	7	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					7d vs 0d		adults (25-42)				28687661	2017	Fig 4d-f	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split into two rows based on figure source. edited response agent (CD3+ was marked B cell instead of T cell). edited source	Amani: added source		peripheral blood mononuclear cell	CL:2000001	B cells CD3-/CD19+CD20+/IgD-IgM-/CD27+; T cells CD3+/CD4+/CD28+; T cells CD3+/CD4+/Ki67+; T cells CD3+/CD8+/CD28+; T cells CD3+/CD8+/Ki67+	cell type frequency	down for	none	7	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					7d vs 0d		adults (25-42)				28687661	2017	Fig 5d-h	 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split into two rows based on figure source	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	Monocytes (CD14+); NK cells (CD14-/CD20-/CD3-/NK/NKP46+)	cell type frequency	down for	none	14	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					14d vs 0d		adults (25-42)				28687661	2017	Fig 4a, Fig 4f, 	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split into two rows based on figure source	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	T cells CD3+/CD4+/Ki67+; T cells CD3+/CD8+/Ki67+	cell type frequency	down for	none	14	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					14d vs 0d		adults (25-42)				28687661	2017	Fig 5f, Fig 5h	 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	plasmacytoid dendritic cell; B cells CD3-/CD19+CD20+; B cells CD3-/CD19+CD20+/IgD-IgM+/CD27+; T cells Cd14-/CD3+/CD4+/IL2+/ENV	cell type frequency	up for	none	28	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					28d vs 0d		adults (25-42)				28687661	2017	text (Vaccination with YF-17D induces...), Fig 4C, Fig 5A-B, Fig 5J	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split row on source	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	NK cells (CD14-/CD20-/CD3-/NK); NK cells (CD14-/CD20-/CD3-/NK/NKG2A+); NK cells (CD14-/CD20-/CD3-/NK/NKP46+)	cell type frequency	down for	none	28	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					28d vs 0d		adults (25-42)				28687661	2017	Fig 4D-F	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F4/ 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split row on source	Amani: added sources		peripheral blood mononuclear cell	CL:2000001	T cells CD3+/CD4+/CD28+; T cells CD3+/CD4+/Ki67+; T cells CD3+/CD8+/Ki67+	cell type frequency	down for	none	28	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					28d vs 0d		adults (25-42)				28687661	2017	 Fig 5E-F, Fig 5H	 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split row on source	Daniel: added source, edited time point & comparison.		peripheral blood mononuclear cell	CL:2000001	DC (NK-/CD123)	cell type frequency	up for	none	86	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					86d vs 0d		adults (25-42)				28687661	2017	Fig 4C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F4/ 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split row on source	Daniel: added source, edited time point & comparison.		peripheral blood mononuclear cell	CL:2000001	B cells CD3-/CD19+CD20+; B cells CD3-/CD19+CD20+/IgD-IgM+/CD27+; B cells CD3-/CD19+CD20+/IgD-IgM-/CD27+; T cells CD14-/CD3+/CD4+/IL2+/NS1	cell type frequency	up for	none	86	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					86d vs 0d		adults (25-42)				28687661	2017	Fig 5A, 5C, 5D, 5I	 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split row on source	Daniel: added source, edited time point & comparison, edited response agent		peripheral blood mononuclear cell	CL:2000001	NK cells (CD14-/CD20-/CD3-/NK); NK cells (CD14-/CD20-/CD3-/NK/NKG2A+); NK cells (CD14-/CD20-/CD3-/NK/NKP46+)	cell type frequency	down for	none	86	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					86d vs 0d		adults (25-42)				28687661	2017	Fig 4D, 4E, 4F,	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F4/ 				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: split row on source	Daniel: added source, edited time point & comparison, edited response agent		peripheral blood mononuclear cell	CL:2000001	T cells CD3+/CD4+/Ki67+; T cells CD3+/CD8+/Ki67+	cell type frequency	down for	none	86	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					86d vs 0d		adults (25-42)				28687661	2017	Fig 5F, 5H	 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: edited response component (4b is a DC, not an NK cell)	Amani: added source, edited comparison		peripheral blood mononuclear cell	CL:2000001	CD11c-positive DC; plasmacytoid dendritic cell	cell type frequency	up for	none	86	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					86d vs 0d		adults (25-42)				28687661	2017	text, Fig 4B-C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	B cells CD3-/CD19+CD20+	cell type frequency	up for	none	14	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					14d vs 0d		adults (25-42)				28687661	2017	Fig 5A	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F5/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	DC HLA-DR+CD11c+	cell type frequency	down for	none	14	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					flavivirus infected vs naive participants		adults (25-42)				28687661	2017	Fig 6a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F6/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	DC HLA-DR+CD11c+	cell type frequency	down for	none	28	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					flavivirus infected vs naive participants		adults (25-42)				28687661	2017	Fig 6a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F6/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	NK cells NK/CD107a+/K562	cell type frequency	up for	none	28	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					flavivirus infected vs naive participants		adults (25-42)				28687661	2017	Fig 6b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F6/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel	Amani: added source		peripheral blood mononuclear cell	CL:2000001	NK cells NK/TNFa+/K562	cell type frequency	up for	none	86	Days	time of vaccination (first dose)	Yellow fever virus 17D			YF-17D	VO_0003134					flavivirus infected vs naive participants		adults (25-42)				28687661	2017	Fig 6b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/figure/F6/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681914/	adults	25	42	years	
			daniel: unclear how this should be captured, removed subgroup (included in comparison); bhav & amani see edits to comparison and comments	Ernest, Amani: added source		blood serum	UBERON:0001977	TIV-specific CD8+ GRZ+ T lymphocyte cells	cell type frequency	up for		21	days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2012	2012-2013 seasonal trivalent inactivated influenza vaccine (TIV)	VO_0004899					S2 vs S1 as defined by hierarchical clustering of gene expression	60	adults (18-45)				30843873	2019	Fig 4e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486343/figure/F4/	Clusters S1 and S2 were defined based on hierarchical clustering of gene expression and were shown to be enriched with significantly different levels of influenza specific MN antibodies as well as vaccination routes for d21/d0.			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486343/	adults	18	45	years	
			daniel: unclear how this should be captured, removed subgroup (included in comparison); bhav & amani see edits to comparison and comments	Ernest, Amani: added source		blood serum	UBERON:0001977	T cell responder TIV-specific CD8+ GRZ+ 	cell type frequency	up for		21	days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2012	2012-2013 seasonal trivalent inactivated influenza vaccine (TIV)	VO_0004899					S2 vs S1 as defined by hierarchical clustering of gene expression. Both clusters d21/d0, where each cluster was enriched for a different vaccination route and different levels of antibody response	60	adults (18-45)				30843873	2019	Fig 3f	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486343/figure/F3/	Clusters S1 and S2 were defined based on hierarchical clustering of gene expression and were shown to be enriched with significantly different levels of influenza specific MN antibodies as well as vaccination routes for d21/d0.			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486343/	adults	18	45	years	C1 includes 2/17, 16/18, and 10/17 t.c.-, i.d.-, and i.m.-vaccinated individuals, respectively. C2 includes the other 15/17, 2/18, and 7/17 t.c-, i.d.-, and i.m.-vaccinated individuals
			daniel	Ernest, Amani: re-curated		peripheral blood mononuclear cell	CL:2000001	CD86+ myeloid dendritic cell (DC)	cell type frequency	up for		1	day	time of vaccination (first dose)	Yellow fever virus 17D	11090		YF-17D vaccine	VO_0003134					1d vs 0d	15	adults (18-45)				19029902	2009	Suppl Fig 1c					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/	adults	18	45	years	
			daniel	Ernest, Amani: re-curated		peripheral blood mononuclear cell	CL:2000001	CD86+ myeloid dendritic cell (DC)	cell type frequency	up for		3	days	time of vaccination (first dose)	Yellow fever virus 17D	11090		YF-17D vaccine	VO_0003134					3d vs 1d	15	adults (18-45)				19029902	2009	Suppl Fig 1c					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/	adults	18	45	years	
			daniel	Ernest, Amani: re-curated		peripheral blood mononuclear cell	CL:2000001	CD86+ myeloid dendritic cell (DC); CD86+ monocyte	cell type frequency	up for		3	days	time of vaccination (first dose)	Yellow fever virus 17D	11090		YF-17D vaccine	VO_0003134					3d vs 0d	15	adults (18-45)				19029902	2009	Suppl Fig 1c					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/	adults	18	45	years	
			daniel	Ernest, Amani: re-curated		peripheral blood mononuclear cell	CL:2000001	CD86+ myeloid dendritic cell (DC)	cell type frequency	up for		21	days	time of vaccination (first dose)	Yellow fever virus 17D	11090		YF-17D vaccine	VO_0003134					21d vs 7d	15	adults (18-45)				19029902	2009	Suppl Fig 1c					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/	adults	18	45	years	
			daniel	Ernest, Amani: re-curated		peripheral blood mononuclear cell	CL:2000001	CD86+ plasmacytoid dendritic cell (pDC); CD86+ CD16+ inflammatory monocyte	cell type frequency	up for		7	days	time of vaccination (first dose)	Yellow fever virus 17D	11090		YF-17D vaccine	VO_0003134					7d vs 1d	15	adults (18-45)				19029902	2009	Suppl Fig 1c					https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/	adults	18	45	years	
			daniel: removed subgroup ( included in comparison)	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD4+ T cells	cell type frequency	up for		0	days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluarix	VO_0000045					females vs males	135	adults (50-74)				30873150	2019	Fig 4b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400991/figure/F4/	Caucasion older adults (50-74)			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400991/	adults, seniors	50	74	years	
			daniel: removed subgroup ( included in comparison)	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	NK cell	cell type frequency	up for		0	days	time of vaccination (first dose)	Influenza A virus; Influenza B virus		2010	Fluarix	VO_0000045					males vs females	135	adults (50-74)				30873150	2019	Fig 4b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400991/figure/F4/	Caucasion older adults (50-74)			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400991/	adults, seniors	50	74	years	
			daniel	Ernest, Amani: added source		whole blood	UBERON_0000178	T cells IFNg producing VZV-specific CD4+ 	cell type frequency	up for		72	hours	time of VZV antigen challenge	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					pre-vaccination vs 72hrs post-vaccination	30	adults (70-93)				30247603	2018	Fig 2e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F2/	-2:1 ratio of female:male			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/	seniors	70	93	years	
			daniel: removed CD4+ Ki67+ because not significant, unmerged rows with different sources	Ernest, Amani: added source, edit comparison & baseline, merged rows of same response behavior type & time points		skin of body	UBERON_0002097	T cells CD4+; T cells CD8+	cell type frequency	up for		3	days	time of VZV antigen challenge	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					pre-vaccination vs 3d post-VZV antigen challenge	30	adults (70-93)				30247603	2018	Fig 3a-c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F3/ 	-2:1 ratio of female:male			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/	seniors	70	93	years	
			daniel: removed CD4+ Ki67+ because not significant, unmerged rows with different sources	Ernest, Amani: added source, edit comparison & baseline, merged rows of same response behavior type & time points		skin of body	UBERON_0002097	T cells CD8+ Ki67+	cell type frequency	up for		3	days	time of VZV antigen challenge	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					pre-vaccination vs 3d post-VZV antigen challenge	30	adults (70-93)				30247603	2018	Fig 4b-c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F4/	-2:1 ratio of female:male			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/	seniors	70	93	years	
			daniel: removed CD4+ Ki67+ because not significant, unmerged rows with different sources	Ernest, Amani: see D142		skin of body	UBERON_0002097	T cells CD4+; T cells CD8+	cell type frequency	up for		7	days	time of VZV antigen challenge	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					pre-vaccination vs 7d post-VZV antigen challenge	30	adults (70-93)				30247603	2018	Fig 3a-c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F3/ 	-2:1 ratio of female:male			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/	seniors	70	93	years	
			daniel: removed CD4+ Ki67+ because not significant, unmerged rows with different sources	Ernest, Amani: see D142		skin of body	UBERON_0002097	T cells CD8+ Ki67+	cell type frequency	up for		7	days	time of VZV antigen challenge	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					pre-vaccination vs 7d post-VZV antigen challenge	30	adults (70-93)				30247603	2018	Fig 4b-c	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F4/	-2:1 ratio of female:male			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/	seniors	70	93	years	
			daniel	Ernest, Amani: source, edit comparison & baseline		skin of body	UBERON_0002097	T cells CD4+ Tregs Foxp3+	cell type frequency	down for		3	days	time of VZV antigen challenge	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					pre-vaccination vs 3d post-VZV antigen challenge	30	adults (70-93)				30247603	2018	Fig 4e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F4/	-2:1 ratio of female:male			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/	seniors	70	93	years	
			daniel	Ernest, Amani: see D144		skin of body	UBERON_0002097	T cells CD4+ Tregs Foxp3+	cell type frequency	down for		7	days	time of VZV antigen challenge	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					pre-vaccination vs 7d post-VZV antigen challenge	30	adults (70-93)				30247603	2018	Fig 4e	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F4/	-2:1 ratio of female:male			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/	seniors	70	93	years	
			daniel: added subgroup	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	CD3- CD56dim Natural Killer cells	cell type frequency	up for	high antibody responders	14	days	time of vaccination (first dose)	Human immunodeficiency virus 1 			CN54gp140 	VO_0004891					14d vs 0hr	14	adults (18-45)	GLA-AF			29535712	2018	Fig 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/figure/F4/	-1 intramuscular dose			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/	adults	18	45	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ 	cell type frequency	up for		30	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					30d vs 0d	25	young adults (25-40)				28607114	2017	Fig 1a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults	25	40	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ 	cell type frequency	up for		30	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					30d vs 0d	33	senior adults (60-80)				28607114	2017	Fig 1a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	seniors	60	80	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ 	cell type frequency	up for		90	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					90d vs 0d	25	young adults (25-40)				28607114	2017	Fig 1a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults	25	40	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ 	cell type frequency	up for		90	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					90d vs 0d	33	senior adults (60-80)				28607114	2017	Fig 1a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	seniors	60	80	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ 	cell type frequency	up for		180	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					180d vs 0d	33	senior adults (60-80)				28607114	2017	Fig 1a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	seniors	60	80	years	
			daniel: edited comparison	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ 	cell type frequency	up for		0	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					young adults vs old adults	58	young adults (25-40), senior adults (60-80)				28607114	2017	Fig 1a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults, seniors	25	80	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ 	cell type frequency	down for		180	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					young adults vs old adults	58	adults (25-80)				28607114	2017	Fig 1a	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults, seniors	25	80	years	
			daniel: edited comparison	Ernest, Amani: added source, edit time 		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ IL2+ BCL2+ 	cell type frequency	up for		30	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					30d vs 0d	25	young adults (25-40)				28607114	2017	Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults	25	40	years	
			daniel: edited comparison	Ernest, Amani: added source, edit time 		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ IL2+ BCL2+ 	cell type frequency	up for		30	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					30d vs 0d	33	senior adults (60-80)				28607114	2017	Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	seniors	60	80	years	
			daniel	Ernest, Ernest, Amani: added source, edit comparison		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ IL2+ BCL2+ 	cell type frequency	down for		180	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					180d vs 0d	25	young adults (25-40)				28607114	2017	Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults	25	40	years	
			daniel	Ernest, Amani: added source, edit comparison, deleted row that was not indicated if it was significant		peripheral blood mononuclear cell	CL:2000001	memory T cells VZV-specific CD4+ IL2+ BCL2+ 	cell type frequency	up for		180	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124					180d vs 0d	33	senior adults (60-80)				28607114	2017	Fig 1b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F1/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	seniors	60	80	years	
			daniel	Ernest, Amani: added source, deleted 2 rows indicated not significant, but marginal in paper		peripheral blood mononuclear cell	CL:2000001	T cells Dual-function VZV-specific CD8+ 	cell type frequency	up for		7	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124	ex-vivo restimulation with live VZV				7d vs 0d	25	young adults (25-40)				28607114	2017	Fig 2b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F2/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults	25	40	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	VZV-specific CD8+ CD69+ CD57+ cells	cell type frequency	up for		0	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124	ex-vivo restimulation with live VZV				old adults vs young adults	58	adults (25-80)				28607114	2017	Fig 3a-b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults, seniors	25	80	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	VZV-specific CD8+ CD69+ PD1+ cells	cell type frequency	up for		0	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124	ex-vivo restimulation with live VZV				old adults vs young adults	58	adults (25-80)				28607114	2017	Fig 3a-b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults, seniors	25	80	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	VZV-specific CD8+ CD69+ CD57+ cells	cell type frequency	up for		7	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124	ex-vivo restimulation with live VZV				old adults vs young adults	58	adults (25-80)				28607114	2017	Fig 3b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults, seniors	25	80	years	
			daniel	Ernest, Amani: added source		peripheral blood mononuclear cell	CL:2000001	VZV-specific CD8+ CD69+ CD57+ cells	cell type frequency	up for		30	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124	ex-vivo restimulation with live VZV				old adults vs young adults	58	adults (25-80)				28607114	2017	Fig 3b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F3/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	adults, seniors	25	80	years	
			daniel: changed behavior from 'up' to 'negative'	Ernest, Amani: edited resp behavior. added source, subgroup		peripheral blood mononuclear cell	CL:2000001	VZV-specific CD4+ CD69+ CD57+ PD1+ cells	cell type frequency	negatively correlated with 	older adults	30	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124	ex-vivo restimulation with live VZV				gain in VZV-specific RCF post-vaccination at 30d vs 0d	33	senior adults (60-80)				28607114	2017	Fig 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	seniors	60	80	years	
			daniel: changed response from 'positive' to 'negative'	Ernest, Amani: edited resp behavior. added source, subgroup		peripheral blood mononuclear cell	CL:2000001	cytotoxic T lymphocytes VZV-specific CD8+ IFNg+ CD107a+ 	cell type frequency	correlated with 	older adults	7	days	time of vaccination (first dose)	Human alphaherpesvirus 3	10335		Zostavax	VO_0000124	ex-vivo restimulation with live VZV				decrease in VZV-specific CD8+CD69+CD57+PD1+ at 7d vs 0d	33	senior adults (60-80)				28607114	2017	Fig 4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/figure/F4/				https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505810/	seniors	60	80	years	
			.	Ernest, Daniel: added source		whole blood	UBERON_0000178	neutrophil; monocyte	cell type frequency	up for		1	day	time of vaccination (first dose)	Influenza A virus (A/Indonesia/5/2005(H5N1))		2005mv	inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine	VO_0004903					1d vs 0d	20	adults (18-49)	AS03 (VO_0001320)			28099485	2017	Fig A212-213 and Tables A161-A162 in S2 Text	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/#pone.0167488.s012	-taken subcutaneous			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/	adults	18	49	years	
			.	Ernest, Daniel: added source		whole blood	UBERON_0000178	monocyte; dendritic cell	cell type frequency	up for		3	days	time of vaccination (first dose)	Influenza A virus (A/Indonesia/5/2005(H5N1))		2005mv	inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine	VO_0004903					3d vs 0d	20	adults (18-49)	AS03 (VO_0001320)			28099485	2017	Fig A212-213 and Tables A161-A162 in S2 Text	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/#pone.0167488.s012	-taken subcutaneous			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/	adults	18	49	years	
			daniel	Ernest, Amani: add source, resp components, merged rows		whole blood	UBERON_0000178	CD16+ HLA-DR++ CD14+ monocytes; CD69+ CD19+ B-cells; CXCR4+ CD8+ T-cells; CD69+ CD8+ T-cells; CCR5+ CD4+ T-cells; CD54+ CD4+ T-cells; CD69+ CD4+ T-cells	cell type frequency	up for		3	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		2009mv	Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)	VO_0000160					3d vs 0d	20	adults (21-51)				28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel: added HLA-DR+ CD8+ T Cells	Ernest, Amani: add source, resp components, merged rows		whole blood	UBERON_0000178	CD16+ CD56+ CD3- Natural Killer cells; CD16+ CD56+ CD3+ Natural Killer cells; HLA-DR+ CD4+ T-cells; HLA-DR+ CD8+ T-cells	cell type frequency	down for		3	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		2009mv	Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)	VO_0000160					3d vs 0d	20	adults (21-51)				28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source, resp components, merged rows		whole blood	UBERON_0000178	CD69+ CD19+ B-cells; CCR3+ CD4+ T-cells; CCR5+ CD4+ T-cells; CXCR4+ CD8+ T-cells	cell type frequency	up for		7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		2009mv	Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)	VO_0000160					7d vs 0d	20	adults (21-51)				28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Amani: add source, resp components, merged rows		whole blood	UBERON_0000178	HLA-DR++ CD16+ CD14+ monocytes; CCR2+ CD14+ monocytes; CD16+ CD56+ CD3+ Natural Killer cells; CD69+ CD4+ T-cells; CD25high CD4+ T-cells; HLA-DR+ CD4+ T-cells; HLA-DR+ CD8+ T-cells; CD38+ CD8+ T-cells	cell type frequency	down for		7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		2009mv	Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)	VO_0000160					7d vs 0d	20	adults (21-51)				28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source, resp components, merged rows		whole blood	UBERON_0000178	HLA-DR++ CD16+ CD14+ monocytes; CD25+ CD4+ T-cells; CCR3+ CD4+ T-cells; CCR5+ CD4+ T-cells; CXCR3+ CD4+ T-cells; CD69+ CD8+ T-cells; CD25+ CD8+ T-cells; CCR3+ CD8+ T-cells; CD5+ CD19+ B-cells; CD69+ CD19+ B-cells	cell type frequency	up for		30	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		2009mv	Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)	VO_0000160					30d vs 0d	20	adults (21-51)				28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: added entry		whole blood	UBERON_0000178	CD54+ CD4+ T-cells; CXCR4+ CD4+ T-cells; CD38+ CD8+ T-cells; CCR5+ CD14+ monocytes	cell type frequency	down for		30	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		2009mv	Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)	VO_0000160					30d vs 0d	20	adults (21-51)				28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source, resp components, merged rows		whole blood	UBERON_0000178	CD64+ CD14+ monocytes; CCR2+ CD14+ monocytes; CCR5+ CD14+ monocytes; CD14+ monocytes; CD19+ B-cells; CD5+ CD19+ B-cells; CD69+ CD4+ T-cells; HLA-DR+ CD4+ T-cells; CCR3+ CD4+ T-cells; CCR5+ CD4+ T-cells; CXCR4+ CD4+ T-cells; HLA-DR+ CD8+ T-cells; CXCR3+ CD8+ T-cells; CXCR4+ CD8+ T-cells	cell type frequency	up for		1	day	time of vaccination (first dose)	Influenza A virus (H1N1)		pan	Pandemrix	VO_0000410					1d vs 0d	20	adults (21-51)	AS03 (VO_0001320)			28549970	2017	Fig 2: black bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Amani: add source, resp components, merged rowsErnest, 		whole blood	UBERON_0000178	HLA-DR+ CD8+ T-cells; CD69+ CD8+ T-cells; CXCR4+ CD8+ T-cells; CD19+ CD69+ B-cells; HLA-DR+ CD4+ T-cells; CD69+ CD4+ T-cells; CXCR4+ CD4+ T-cells; CCR3+ CD4+ T-cells; CD16+ CD56+ CD3+ Natural Killer cells	cell type frequency	down for		1	day	time of vaccination (first dose)	Influenza A virus (H1N1)		2009mv	Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur)	VO_0000160					1d vs 0d	20	adults (21-51)				28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source, resp components, merged rows		whole blood	UBERON_0000178	HLA-DR++ CD16+ CD14+ monocytes; CD64+ CD14+ monocytes; CD69+ CD4+ T-cells; CD54+ CD4+ T-cells; CCR5+ CD4+ T-cells; CXCR3+ CD4+ T-cells; CD69+ CD8+ T-cells; CD25+ CD8+ T-cells; CCR3+ CD8+ T-cells	cell type frequency	up for		3	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					3d vs 0d	20	adults (21-51)	AS03 (VO_0001320)			28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source		whole blood	UBERON_0000178	CD69+ CD19+ B-cells	cell type frequency	down for		3	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					3d vs 0d	20	adults (21-51)	AS03 (VO_0001320)			28549970	2017	Fig 2: grey bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source, resp components, merged rowsErnest, 		whole blood	UBERON_0000178	HLA-DR++ CD16+ CD14+ monocytes; CCR2+ CD14+ monocytes; CD69+ CD4+ T-cells; HLA-DR+ CD4+ T-cells; CXCR3+ CD4+ T-cells; CD69+ CD8+ T-cells; CD25+ CD8+ T-cells; HLA-DR+ CD8+ T-cells; CCR3+ CD8+ T-cells	cell type frequency	up for		7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					7d vs 0d	20	adults (21-51)	AS03 (VO_0001320)			28549970	2017	Fig 2: black bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source		whole blood	UBERON_0000178	CD16+ CD56+ CD3+ Natural Killer cells	cell type frequency	down for		7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					7d vs 0d	20	adults (21-51)	AS03 (VO_0001320)			28549970	2017	Fig 2: black bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel	Ernest, Amani: add source, merged rows		whole blood	UBERON_0000178	HLA-DR++ CD16+ CD14+ monocytes; CD64+ CD14+ monocytes; CCR2+ CD14+ monocytes; CD16+ CD56+ CD3- Natural Killer cells; CXCR4+ CD4+ T-cells; CXCR4+ CD8+ T-cells; CD32+ CD19+ B-cells; CD69+ CD8+ T-cells; CD25+ CD8+ T-cells; CCR3+ CD8+ T-cells	cell type frequency	up for		30	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					30d vs 0d	20	adults (21-51)	AS03 (VO_0001320)			28549970	2017	Fig 2: black bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel: removed  CD16+ CD14+ monocytes, 	Ernest, Amani: add source & resp component, merged rows		whole blood	UBERON_0000178	total CD14+ monocytes;CCR5+ CD14+ monocytes; CD16+ CD56+ CD3+ Natural Killer cells; CD54+ CD4+ T-cells; CCR3+ CD4+ T-cells; CXCR4+ CD4+ T-cells; CD54+ CD8+ T-cells	cell type frequency	down for		30	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					30d vs 0d	20	adults (21-51)	AS03 (VO_0001320)			28549970	2017	Fig 2: black bars	https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig2	-taken subcutaneous			https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub	adults	21	51	years	
			daniel: edited comparison	Amani		peripheral blood mononuclear cell	CL:2000001	plasma cells	cell type frequency	up for	none	1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					1d vs -7d	178	adults (18-64)	AS03 (GSK)			26726811	2016	Fig 1C-D, Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F1/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: edited comparison	Amani		peripheral blood mononuclear cell	CL:2000001	monocytes; CD16+ inflammatory monocytes	cell type frequency	up for	none	1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					1d  vs  prevax	178	adults (18-64)	AS03 (GSK)			26726811	2016	Fig 1C-D, Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F1/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	all T-cells; gamma-delta cells; CD8+ T cells; CD4+ T cells	cell type frequency	down for	none	1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					1d  vs  prevax	178	adults (18-64)	AS03 (GSK)			26726811	2016	Fig 1C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F1/	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	plasma cell	cell type frequency	up for	none	7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					7d  vs  prevax	178	adults (18-64)	AS03 (GSK)			26726811	2016	Fig 1D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F1/	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	CD69+ gamma-delta T-cell; CD69+ natural killer (NK) cell	cell type frequency	up for		-7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					non-responders vs responders	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 6D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	CXCR3+ CD8+ IFN-gamma producing T-cells	cell type frequency	down for	<35yr old	1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					1d vs 0d	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			.	daniel		peripheral blood mononuclear cell	CL:2000001	CXCR3+ CD8+ IFN-gamma producing T-cells	cell type frequency	down for	<35yr old	1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					1d-(-7d)	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5B	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	CD69+ gamma-delta T-cell; CD69+ natural killer (NK) cell	cell type frequency	up for		0	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					non-responders vs responders	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 6D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	CD69+ gamma-delta T-cell; CD69+ natural killer (NK) cell	cell type frequency	up for		1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					non-responders vs responders	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 6D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	CD69+ gamma-delta T-cell; CD69+ natural killer (NK) cell	cell type frequency	up for		7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					non-responders vs responders	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 6D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani 		peripheral blood mononuclear cell	CL:2000001	CD69+ gamma-delta T-cell; CD69+ natural killer (NK) cell	cell type frequency	up for		14	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					non-responders vs responders	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 6D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani		peripheral blood mononuclear cell	CL:2000001	CD69+ gamma-delta T-cell; CD69+ natural killer (NK) cell	cell type frequency	up for		63	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					1d vs -7d	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 6D	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel	Amani		peripheral blood mononuclear cell	CL:2000001	CD38+ CD8+ T-cells	cell type frequency	down for		0	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					-7d vs 0d, negatively correlated with age	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: edited comparison (removed time point)	Amani		peripheral blood mononuclear cell	CL:2000001	CD45RO+ CCR7+ central memory CD4 cells; CD45RO+ CCR7+ central memory CD8 cells	cell type frequency	up for		-7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					<35yr old vs >35yr old	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: edited comparison (removed time point)	Amani		peripheral blood mononuclear cell	CL:2000001	CD45RO+ CCR7+ central memory CD4 cells; CD45RO+ CCR7+ central memory CD8 cells	cell type frequency	up for		0	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					<35yr old vs >35yr old	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: edited comparison (removed time point)	Amani		peripheral blood mononuclear cell	CL:2000001	CD45RO+ CCR7+ central memory CD4 cells; CD45RO+ CCR7+ central memory CD8 cells	cell type frequency	up for		1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					<35yr old vs >35yr old	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: edited comparison (removed time point)	Amani		peripheral blood mononuclear cell	CL:2000001	CD45RO+ CCR7+ central memory CD4 cells; CD45RO+ CCR7+ central memory CD8 cells	cell type frequency	up for		7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					<35yr old vs >35yr old	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: edited comparison (removed time point)	Amani		peripheral blood mononuclear cell	CL:2000001	CD45RO+ CCR7+ central memory CD4 cells; CD45RO+ CCR7+ central memory CD8 cells	cell type frequency	up for		14	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					<35yr old vs >35yr old	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: edited comparison (removed time point)	Amani		peripheral blood mononuclear cell	CL:2000001	CD45RO+ CCR7+ central memory CD4 cells; CD45RO+ CCR7+ central memory CD8 cells	cell type frequency	up for		63	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					<35yr old vs >35yr old	178	adults (18-64)	AS03 (GSK)			26726811	2016	Suppl Fig 5C	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	
			daniel: added subgroup	Amani: moved from up top, added source		peripheral blood mononuclear cell	CL:2000001	CD8+ CXCR3+ alpha-beta regulatory T cell	cell type frequency	down for	<35yr old	1	day	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					1d vs 0d	178	adults (18-35)	AS03 (GSK)			26726811	2016	Supp Fig 5b	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/#SM	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults	18	35	years	
			daniel	Amani: moved from up top, added source, edit resp component & comparison		peripheral blood mononuclear cell	CL:2000001	CD27+ CD38hi plasmablasts	cell type frequency	up for	none	7	days	time of vaccination (first dose)	Influenza A virus (A/California/7/2009(H1N1))		pan	Pandemrix	VO_0000410					responder vs non-responder	178	adults (18-64)	AS03 (GSK)			26726811	2016	Fig 4d	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F4/	- roughly 60/40 female:male ratio, over 70% were Causasian			https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/	adults, seniors	18	64	years	